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LABORATORY INVESTIGATION
Renal functional changes in experimental cystic disease are
tubular in origin
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and RY0IcHI OYASU
Department of Pathology, Northwestern University School of Medicine, Chicago, Illinois, USA
Chronic functional changes in experimental cystic disease are tubular in
origin. Chronic (30 weeks) structural and functional changes were
correlated in diphenylthiazole (DPT)-induced polycystic kidney disease
(PKD) in rats. DPT induced two different types of progressive tubular
changes: cystic transformation and hyperplastic/atrophic tubular changes.
Cystic changes diffusely involved collecting tubules in the outer me-
dulla and cortex, and they were progressive over 30 weeks. Hyperplas-
tic/atrophic changes occurred as clusters of tubules in the cortex and
involved between 25% and 50% of tubular profiles after 12 and 30 weeks
of drug treatment. Thus, the two types of tubular change were inde-
pendent of each other and represent different cellular responses to the
drug. DPT treatment induced no detectable light- and electron-micr-
oscopic or histochemical alterations in glomeruli or renal blood vessels.
Renal functional changes consisted of: (1) early (4 weeks) and persistent
impairment of concentrating ability; (2) a progressive drop in creatinine
clearance and elevation in BUN; and (3) the late onset (30 weeks) of
moderate proteinuria. These findings suggest that cystic as well as
hyperplastic-atrophic tubular changes contribute to the loss of tubular
and renal function in DPT-induced PKD. Both types of tubular lesions
may have a role in the development of impaired renal function in other
forms of experimental and clinical PKD.
Progression of several forms of polycystic kidney disease
(PKD) is variable and the factors responsible for this variation
are unknown [1, 2]. The progressive loss of renal function in
PKD could be due to: tubular changes; secondary glomerular
changes, such as focal glomerulosclerosis [3]; or vascular
changes secondary to tubulointerstitial disease and/or hyperten-
sion. Few studies in human or experimental forms of PKD have
correlated renal structural and functional changes on a long-
term basis in order to elucidate factors leading to progressive
impairment of renal functions. In this study, renal structural
and functional changes were assessed over a 30-week period in
rats with diphenyithiazole (DPT)-induced PKD [4]. The findings
suggest that renal functional impairment is due primarily to
tubular rather than glomerular or vascular alterations.
Methods
Animals
Seventy, male Sprague-Dawley rats (specific pathogen-free,
The Charles River Breeding Laboratories, Wilmington, Massa-
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chusetts, USA) weighing 180 to 250 g (average 221 g) were used.
Animals were housed four to a plastic cage in an air-conditioned
room at 22°C with 70% humidity under a 12-hour light-dark
cycle.
Chemicals
2-amino-4,5-diphenylthiazole (DPT) was from Travenol Lab-
oratories, Inc., Deerfield, Illinois, USA. Rat chow pellets
containing 1.06% DPT were prepared by Teklad (Madison,
Wisconsin, USA) and commercial stock diet (Purina 5012) was
purchased from Ralston Purina Co. (St. Louis, Missouri, USA).
Groups of DPT-treated and control pair-fed animals were
studied after 0, 4, 8, 12, and 30 weeks of drug administration.
Functional studies
To assess renal concentrating ability, after 16 hours of
dehydration, animals were given 50 milliunits of Pitressin
tannate in oil subcutaneously and placed in individual metabo-
lism cages; urine was collected under oil for a four hour period.
Urine osmolality was determined with an Advanced Instrument
Digimatic Osmometer; blood urea nitrogen (BUN) and serum
and urine creatinine were determined with a Beckman Astra-8;
and total urinary protein was determined by the coomassie blue
method of the Union Carbide/Baker Centrifichem, System 500.
Autoradiography
Three, randomly selected animals of each subgroup received
[methyl-3H] thymidine (Amersham, Arlington Heights, Illinois,
USA) intraperitoneally at a dose of 1 j.Ci/g of body weight one
hour before sacrifice. Mounted sections were processed for
autoradiography using Kodak nuclear track emulsion (Eastman
Kodak Company, Rochester, New York, USA) and exposed in
the dark for two weeks.
Tissue preparation
Under ether anesthesia, the abdomen was approached by a
midline incision, and a clamp was placed on the vascular
pedicle of the right kidney; the kidney was removed and
processed for autoradiography and light microscopy. Then the
aorta was catheterized with polyethylene tubing and the left
kidney was fixed by perfusion in vivo according to the tech-
nique of Kriz [5]. Small (1 mm3) pieces of tissue were processed
for electron microscopy. For light microscopy, 6-jim sections
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Fig. 1. Renal cystic changes after 4 (A), 8 (B), 12 (C), and 30 (D) weeks of DPT treatment. A and B: x9, C and D: X6.
were stained with eosin and hematoxylin, alcian blue, pH 2.5 Results
[6], and colloidal iron [71.
Structural changes
Renal tubules. Animals treated with DPT developed two
different tubular lesions: cystic transformation and hyperplas-
Statistical analysis tic/atrophic change. The cystic change involved apparently all
collecting tubules in the medulla and cortex (Fig. 1). Diffuse
Student t-testing was used to compare differences among nephron and renal involvement may be a unique feature of DPT
groups. Statistical significance was defined as P < 0.05. [4] compared to other experimental drugs that induce PKD [1,
C 
-
 
10 Carone et a!: Nature of functional loss in cystic disease
Fig. 2. Hyperplastic/atrophic tubular foci after 4 (A) and 30 (B) weeks of DPT treatment, In A, the presence of a brush border (arrows) indicates
involvement of proximal tubules. In B, the cluster of atrophic tubules with thickened basement membranes is surrounded by cystic tubules (C).
x 100.
8]. Cystic change of collecting tubules became more marked
with time so that the renal parenchyma was clearly spongiform
at 30 weeks (Fig. 1D), Epithelial papillary projections or
micropolyps were not seen in cystic or noncystic tubules of
DPT-treated animals, however, as reported by Gardner and
Evan [9], these may have been present prior to four weeks
when tubular cell proliferation is maximal in DPT-treated
animals. Hyperplastic/atrophic changes consisted of clusters of
tubules largely in the inner cortex and involved less than 25% of
the tubular profiles at four weeks, At this time, the tubules were
hyperplastic with an increased number of enlarged cells con-
taining large hyperchromatic nuclei (Fig. 2A). Some hyperplas-
tic changes could be identified as originating in proximal tubules
by the presence of brush borders (Fig. 2A). With continued
drug treatment, hyperplastic tubules became atrophic and were
associated with basement membrane (BM) thickening and in-
terstitial fibrosis (Fig. 2B). At 12 and 30 weeks, these tubular
changes involved between 25% and 50% of tubular profiles in
the cortex.
Following four weeks of DPT treatment, kidneys processed
for autoradiography revealed that 1.4% of cells in the medullary
collecting tubules were labeled with tritiated thymidine and that
0.5% of cells displayed mitotic figures. In cortical hyperplastic
tubules, 1.3% of the cells were labeled with tritiated thymidine
and only an occasional cell had a mitotic figure. Following 8, 12,
or 30 weeks of DPT treatment, thymidine labeling of cells or
mitosis were infrequent both in collecting tubules and hyper-
plastic/atrophic tubules.
Glomeruli. Up to 30 weeks there were no significant glomer-
ular changes by light or electron microscopy in DPT-treated
animals compared to controls (Figs. 3 and 4). At 30 weeks,
when cystic and atrophic tubular changes and loss of renal
function were marked, glomeruli by light microscopy were not
hypercellular, hyalinized, or sclerotic, and their capillaries were
patent (Fig. 3). At the ultrastructural level, glorneruli in DPT-
treated and control animals revealed no significant changes
Fig. 3. Glomeruli from 30-week control (A, C) and DPT-treated (B, D)
animals stained with alcian blue (A and B) and colloidal iron (C andD).
x125.
involving the mesangium, endothelial cells, glomerular base-
ment membrane (GBM), or epithelial cells including the foot
processes (Fig, 4). GBMs were uniformly of normal thickness
and electron density, and mesangial regions were not
hypercellular or expanded (Fig. 4). Staining of GBMs with
alcian blue and colloidal iron was equally intense in DPT-
treated and control kidneys (Fig. 3). Renal arteries and arteri-
oles in DPT-treated and control animals showed no significant
endothelial proliferation, medial thickening, or hyaline change.
Similarly, renal veins and medullary vasa rectae appeared
normal morphologically in both groups of animals,
Functional changes
Animals treated with DPT for four weeks, when renal cystic
changes were mild to moderate in degree, had significantly
elevated BUN and reduced renal creatinine clearance corn-
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Fig. 5. Renalfunctiona! parameters in control and DPT-treated animals
during a 30-week experimental period. Values are means SE. *
0.05.
pared to controls (Fig. 5). BUN rose progressively during the
30-week experimental period (Fig. 5), while creatinine clear-
ance fell to about 40% of control values at weeks 12 and 30 in
DPT-treated animals.
In DPT-treated animals, total urinary protein was unchanged
compared to controls at 4, 8, and 12 week periods (Fig. 5). At 30
weeks, however, total urinary protein was increased about
sevenfold in DPT-treated animals (Fig. 5). In DPT-treated
animals, renal concentrating ability was markedly impaired at
all experimental intervals (Fig. 5).
Discussion
Long term (30 weeks) PKD induced by DPT in rats resulted
in sequential renal functional changes with the early onset of
impaired concentrating ability, reduced creatinine clearance
and elevated BUN, and a late onset of proteinuria. Earlier
studies with this model [10, 11] indicate that the urine concen-
trating defect precedes the development of tubular changes,
was due either to a decreased number of cell surface vasopres-
sin receptors or impaired coupling between the receptor and the
adenylate cyclase complex [111, and that the concentrating
defect was reversible following removal of DPI' [121. This
study, however, reveals that with drug treatment the renal
Fig. 4. Electron micrograph of glomeruli from control (A) and DPI'-
treated (B) animals after 30 weeks. Me, mesangial cell; Cap, capillary;
En, endothelial cell; GBM, glomerular basement membrane; Ep, epi-
thelial cell; Fp, foot processes; US, urinary space. x3600.
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concentrating defect can persist for up to 30 weeks. In human
forms of PKD, loss of renal concentrating ability in the pres-
ence of minimal morphological changes is a common early
functional change [1, 13].
In animals treated with DPT, progressive renal failure could
not be attributed to glomerular or vascular changes since no
significant alterations were detected in these structures by light
or electron microscopy. Loss of renal function was apparently
due primarily to tubular changes. DPT induced two types of
tubular change: (1) progressive cystic change of all collecting
tubules; and (2) foci of tubular hyperplasia in the cortex, which
with time became atrophic. These changes have a number of
features in common with human infantile (autosomal recessive)
PKD and medullary cystic PKD (nephronophthisis) [2]. In the
severe forms of infantile PKD with early death, cystic change is
marked and involves the collecting tubules diffusely, and other
tubules are not hyperplastic or atrophic. In less severe forms of
infantile PKD with survival beyond infancy, cystic change is
less prominent, but variable degrees of cortical tubular atrophy,
BM thickening, and interstitial fibrosis are present, which may
be a primary manifestation of the disease. These observations
suggest that rapid progression to death does not allow the
development of hyperplastic/atrophic tubular changes in the
severe forms of this entity. In medullary cystic PKD, cystic
change involves only a small number of collecting tubules in the
medulla; however, the predominant lesions are in the cortex
and consist of tubular atrophy with a variety of tubular base-
ment membrane (TBM) alterations [14, 15]. Thus, in the less
severe form of infantile PKD and in medullary cystic disease,
morphological studies support the concept that tubular atrophy
and BM changes develop independently of cystic change and
contribute to the loss of renal function.
In autosomal dominant PKD, cystic change can develop in
any segment of the nephron and the glomerular capsule. Paren-
chyma between cysts usually reveals severe tubular atrophy,
TBM thickening, and interstitial fibrosis; however, whether this
is due to the primary disease process or is secondary to cyst
growth is unknown. The origin of tubular atrophy in autosomal
dominant PKD is unclear, but the recent finding that a relatively
small number of nephrons develop cysts in this entity [161,
raises the possibility that tubular atrophic changes are a primary
component of the disease. Taken together, our experimental
findings raise the possibility that tubular cell responses to
genetic or environmental stresses in human forms of PKD are
varied and may result in the development of either tubular cysts
or hyperplasia/atrophy, which individually contribute to loss of
renal function.
Proteinuria was observed only after 30 weeks of DPT treat-
ment and was not accompanied by any significant glomerular
structural alterations by light and electron microscopy. Alcian
blue and colloidal iron, which bind to glyco- and sialo-proteins
in the GBM, stained the GBM of PKD kidneys with the same
intensity as controls. This finding suggests no change in the net
negative charge and presumably in the permselectivity of the
GBM [17]. Collectively, these data support the conclusion that
the proteinuria was not glomerular in origin. Preuss et al
reported proteinuria in five of eight patients with autosomal
dominant [13] PKD, and Bricker and Patton found that the
protein content of seven samples of cystic fluid from one
kidney with this disease varied between 0.5 and 3.5 g/dl [18].
Similarly, we found a high protein content in 20 samples of cyst
fluid from four kidneys with autosomal dominant PKD, which
had a mean total protein of 2.39 g/dl with a range of 0.5 to 5.1
and did not contain detectable amounts of hemogloblin (unpub-
lished observations). The high protein content in cyst fluid
could originate from the glomerular filtrate, by diffusion from
the interstitial fluid, or by leakage out of the numerous capil-
laries in the cyst wall. The latter is unlikely since in our studies
cyst fluid did not contain hemoglobin. Findings in this study
suggest that the high protein content in cyst fluid is not
glomerular in origin. Thus, in PKD, proteinuria may be due to
diffusion of interstitial protein across the altered cystic or
noncystic tubules. Birenboim et al found that proximal cysts in
autosomal dominant PKD are permeable to f32-microglobulin
[16].
Several studies in experimental and human PKD indicate that
tubular cell hyperplasia plays an important role in the develop-
ment and growth of cysts [19, 20]. Early changes following the
administration of DPT consist of degeneration and focal necro-
sis followed by an accelerated rate of proliferation of cells in
medullary collecting tubules. This study and an earlier reported
study [9] indicate that at later time periods the rate of cell
proliferation is not significantly increased and that the tubules
are lined by morphologically and metabolically altered cells
[12]. These findings suggest that DPT initially induces cell
injury which is followed by a brisk proliferative response. With
time, the rate of cell proliferation returns to low levels, but in
the presence of DPT the cells remain modified and exhibit
altered biological behavior with the development of cysts or
hyperplastic/atrophic changes. Growth of cysts at this stage
may be due to a slightly increased rate of cell proliferation
and/or to prolonged cell life span.
The degree of renal functional impairment due to either
tubular cyst formation or hyperplastic/atrophic changes could
not be quantified in this study. We have determined by micro-
dissection that DPT induces cystic change in all collecting
tubules [4], and findings in this study demonstrated that cystic
change was progressive for up to 30 weeks of treatment (Fig. 1).
This would suggest that progressive cystic transformation con-
tributed importantly to renal functional impairment by impinging
on adjacent renal parenchyma. Hyperplastic/atrophic changes
involved less than 25% of tubular profiles in histological sec-
tions after four and eight weeks of DPT treatment and involved
between 25% and 50% of tubular profiles after 12 and 30 weeks
of DPT treatment. From tissue sections alone, the percentage of
nephrons with hyperplastic/atrophic lesions could not be deter-
mined; however, their relatively high frequency suggests that
they also contributed significantly to the impairment of renal
function.
In summary, renal functional changes in DPT-induced PKD
may be due to tubular and not glomerular alterations. Hyper-
plastic/atrophic tubular changes, in addition to cystic transfor-
mation, appeared to contribute to the impairment of renal
function. Similar tubular changes may contribute to the patho-
genesis and functional changes in other experimental and
clinical forms of PKD.
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